Abstract:Background and Objectives Ezetimibe/simvastatin combination tablet has been approved for the treatment of high low-density lipoprotein cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia or mixed hypercholesterolaemia as adjunctive therapy to diet, when diet alone is insufficient in lowering cholesterol. The aims of this study were to assess the pharmacokinetics and safety of an ezetimibe/simvastatin combination tablet after oral single-dose administration in healthy Chinese subjects including sex-related differences in pharmacokinetics. Methods This was an open-label, single-dose study. Twelve healthy subjects (six males and six females) received a single dose of an ezetimibe/simvastatin combination tablet (ezetimibe 10 mg and simvastatin 40 mg). The pharmacokinetic parameters for ezetimibe and simvastatin were assessed by determining total ezetimibe, free ezetimibe, simvastatin and simvastatin acid concentrations using a validated liquid chromatography–tandem mass spectrometry method. Safety was evaluated by monitoring adverse events, laboratory assays, vital signs, physical examinations and 12-lead electrocardiograms. Results The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C max ) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C max (t max ) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t ½ ) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration–time curve from time zero to the time of the last measurable concentration (AUC last ) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively. The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C max 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t max 0.98 ± 0.28 and 3.73 ± 1.68 h, t ½ 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC last 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL. Higher AUC last and AUC from time zero to infinity (AUC ∞ ), and lower apparent total body clearance of drug from plasma after oral administration (CL/F) for total ezetimibe and free ezetimibe were observed in female subjects compared with those in male subjects. There were no differences between the pharmacokinetic parameters of simvastatin and simvastatin acid for female and male subjects in the study. Conclusion Ezetimibe/simvastatin combination tablet has a generally favourable safety and tolerability profile in healthy Chinese subjects. A statistically significant difference with regard to sex in the pharmacokinetics of ezetimibe was observed. Sex had no effect on the pharmacokinetics of simvastatin and simvastatin acid.

Study on the Effect of Fenofibrate to Pharmacokinetics of Simvastatin in Healthy Volunteers

Absolute Oral Bioavailability of Fenofibric Acid and Choline Fenofibrate in Rats Determined by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

[Efficacy and Safety of Combination Therapy with Simvastatin and Fenofibrate for Combined Hyperlipidemia].

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Effect of Food on Pharmacokinetics and Pharmacodynamics of Fenofibric Acid aftera Single Oral Dose of Fenofibrate Sustained-Release Capsule

GW24-e0076 Safety of fenofibrate-statin therapy versus statin alone: a meta-analysis

The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteers’ plasma

The Effects of Food on the Bioavailability of Fenofibrate Administered Orally in Healthy Volunteers via Sustained-Release Capsule

Enhanced Bioavailability of the Poorly Water-Soluble Drug Fenofibrate by Using Liposomes Containing a Bile Salt

Effects of Micronised Fenofibrate on Lipid and Uric Acid Metabolism in Elderly Patients with Metabolic Syndrome

[A meta-analysis on the safety of combination therapy with fenofibrate and statins].

SAFETY OF FENOFIBRATE-STATIN THERAPY VERSUS STATIN ALONE: A META-ANALYSIS

Pharmacokinetics and Bioequivalence of Fixed‐Dose Combination of Simvastatin and Ezetimibe Tablets: A Randomized, Crossover, Open‐Label Study in Healthy Volunteers

Adverse Events Following Statin-Fenofibrate Therapy Versus Statin Alone: A Meta-Analysis of Randomized Controlled Trials

A Survey on the Efficacy and Tolerability of Micronized Fenofibrate in Patients with Dyslipidemia.

[Effects of Micronized Fenofibrate on Lipid and Uric Acid Metabolism in Patients with Hyperlipidemia].

The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet

Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet